Lung reduction surgery risky for certain emphysema patients

September 28, 2001

New York, NY -- The National Emphysema Treatment Trial (NETT), in which Columbia Presbyterian Medical Center of NewYork-Presbyterian Hospital is a major participant, has found that certain advanced emphysema patients benefit little from Lung Volume Reduction Surgery (LVRS) and are at unacceptable risk of death from the procedure.

The NETT trial -- a five-year, multicenter, randomized study designed to evaluate the role of LVRS in the treatment of severe emphysema -- indicates that those patients who have severe lung obstruction with either limited ability to exchange gas while breathing or damage that is evenly distributed throughout their lungs should not undergo LVRS.

This is the first time that researchers have identified scientifically based selection criteria for patients seeking LVRS for advanced emphysema. As a result, patients with these high-risk characteristics are no longer being enrolled in NETT. However, the study will continue to recruit other eligible patients until its scheduled completion in 2002.

"Learning when not to perform lung volume reduction surgery is clearly one of the great benefits of NETT," said Dr. Mark Ginsburg, the principal investigator of NETT, assistant clinical professor of surgery, Columbia University College of Physicians and Surgeons and surgical director of the Center for Chest Disease, Columbia Presbyterian Medical Center of NewYork-Presbyterian Hospital. "We remain guardedly hopeful that for other patients LVRS may prove to be of value." Dr. Ginsburg is associate director of thoracic surgery at the medical center.

"The NETT hopes to define a role for LVRS in patients with advance emphysema," said Dr. Byron Thomashow, clinical profesor of medicine at Columbia University College of Physicians and Surgeons and attending physician at Columbia Presbyterian Medical Center. "The preliminary results released by the NHLBI established a subgroup of patients who do not benefit from LVRS Surgery. As the trial moves toward completion, investigators believe that scientifically based selection criteria for the procedure will be established."

Dr. Claude Lenfant, director of the National Heart, Lung, and Blood Institute (NHLBI), the primary sponsor of the study, said, "This is exactly the kind of insight we hope to gain from NETT. We expect the final results of NETT will guide us further in determining if and when this procedure should be used to treat emphysema."

The findings are being posted on the Web site of the New England Journal of Medicine http://www.nejm.org on August 14. Because of the importance of the results the NEJM editors agreed to expedite their review of the findings and to publish them on their Internet site prior to printing the investigators' report within the next few months.

The largest study of its kind, NETT compares the safety and effectiveness of LVRS with medical treatment in patients with end-stage emphysema. The study also aims to define better who benefits from LVRS and who is at excessive risk of complications or death from the procedure. More than 1,000 participants at 17 clinical sites have enrolled in NETT since 1997.

In emphysema, the fine architecture of the lung is destroyed, leading to large holes in the lung, obstruction of the airways, trapping of air, and difficulty exchanging oxygen. Current medical treatments include supportive measures such as medications, exercise rehabilitation, and nutritional supplementation.

LVRS is an unproven modality to ease symptoms associated with advanced emphysema and to improve overall lung function. The procedure is believed by some to improve the ability to move air in and out of the lungs by surgically removing as much as one-third of each lung, targeting the most damaged regions with the expectation that the remaining lung will have better air exchange.

NETT was developed in response to concerns from both the medical community and the Center for Medicare and Medicaid Services (formerly the Health Care Financing Administration) about the risks and benefits of LVRS compared to medical treatment.

During its quarterly review of the study data in May 2001, the NETT Data and Safety Monitoring Board (DSMB) found that a subgroup of participants undergoing the procedure had a 30-day post-surgery death rate considered unacceptable based on the study's safety and monitoring guidelines.

The DSMB is a group of experts who are unaffiliated with NETT and who are responsible for overseeing participants' safety and outcomes data. In addition, the NETT DSMB is charged with identifying subgroups of patients who may benefit from or be at high risk of dying from LVRS.

As a result of the DSMB's findings, NETT is no longer enrolling patients with severe obstruction in the lung as measured by a forced expiratory volume in one second less than or equal to 20 percent of predicted, plus one of the following characteristics: severe loss of lung surface area as measured by a diffusing capacity of less than 20 percent predicted or homogeneous damage to the lung -- that is, disease is evenly distributed throughout the lung, rather than being confined to certain areas.

Of the 1,033 current participants, 140 (14%) met these high-risk criteria, 69 of whom underwent surgery as part of the trial. These patients had a 16% 30-day mortality rate. In contrast, no deaths were reported in the medical treatment group 30 days following the start of medical treatment.

Furthermore, compared to similar participants who received only medical treatment, high-risk participants who survived the surgery were found to have only slightly improved functional outcomes and quality-of-life scores six months after enrolling in the study.

In addition to NHLBI, which is part of the National Institutes of Health, NETT is supported by the Center for Medicare and Medicaid Services, which supports clinical services for the study, and the Agency for Healthcare Research and Quality.

Emphysema is a disabling condition that affects approximately 2 million Americans, most of them over age 50. Typically caused by cigarettes, emphysema costs more than $2.5 billion in annual healthcare expenses and kills more than 16,000 people in the U.S. each year.
-end-


Columbia University Medical Center

Related Emphysema Articles from Brightsurf:

Lung-specific risk factors may increase hip fracture risk in individuals who smoke
Smoking has been linked to a higher risk of bone fractures.

A targeted treatment for emphysema?
Emphysema is a progressive, debilitating lung disease in which the lung's breathing sacs, or alveoli, enlarge, get thinner, and eventually are destroyed as the cells die off.

E-cigs can trigger same lung changes seen in smokers, emphysema
In a study published in the American Journal of Respiratory and Critical Care Medicine, the UNC scientists found that the lungs of vapers -- like the lungs of smokers -- have elevated levels of protease enzymes, a condition known to cause emphysema in smokers.

Exposure to outdoor air pollutants, change in emphysema, lung function
Whether exposure to outdoor air pollutants is associated with emphysema progression and change in lung function was the focus of this observational study.

Study finds link between long-term exposure to air pollution and emphysema
Long-term exposure to air pollution was linked to increases in emphysema between 2000 and 2018, according to a new study funded by the National Institute of Environmental Health Sciences (NIEHS) and the National Heart, Lung, and Blood Institute (NHLBI), both part of the National Institutes of Health.

Pollutant linked to climate change accelerates lung disease
A new multicenter study at Columbia University links long-term exposure to air pollution, especially ozone, to development of emphysema, accelerating lung disease progression as much as a pack a day of cigarettes.

Piedmont Atlanta first in Georgia to offer new minimally invasive treatment for emphysema
Piedmont Atlanta Hospital is the first in the state of Georgia to offer a new minimally invasive treatment for emphysema, a severe form of Chronic Obstructive Pulmonary Disease (COPD).

MedStar Franklin Square to offer new treatment option for qualified emphysema patients
MedStar Franklin Square is the first medical facility in the state to offer endoscopic lung volume reduction (ELVR), using a new FDA-approved lung valve that is positioned in damaged lung airways without surgery, and allows patients with severe emphysema to breathe easier.

Protein may slow progression of emphysema, Rutgers study finds
A protein generated as part of our body's immune response to intestinal worms could slow the progression of emphysema, according to a Rutgers study.

Temple Lung Center director reports ongoing positive results for emphysema treatment study
Dr. Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University, announced the 12-month results of the EMPROVE multicenter, randomized and controlled study for the Spiration® Valve System (SVS), a minimally invasive treatment for severe emphysema, at the European Respiratory Society International Congress (ERS) in Paris, France, on Sept.

Read More: Emphysema News and Emphysema Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.